ISCOMs: an adjuvant with multiple functions
暂无分享,去创建一个
I. Barr | A. Sjölander | Anders Sjölander | John C. Cox | Ian G. Barr | J. Cox | J. Cox
[1] J. Bates,et al. Development of an Influenza-Iscom™ Vaccine , 1997 .
[2] C. Kensil,et al. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. , 1992, Journal of immunology.
[3] G. Wulff,et al. Chemie und Biologie der Saponine , 1973 .
[4] J. Brewer,et al. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems. , 1996, Vaccine.
[5] E. Tulman,et al. Delivery of pseudorabies virus envelope antigens enclosed in immunostimulating complexes (ISCOMs); elicitation of neutralizing antibody and lymphoproliferative responses in swine and protection in mice. , 1994, Vaccine.
[6] R. Rerko,et al. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. , 1995, Journal of immunology.
[7] H. Braley‐Mullen,et al. Immunopotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens. , 1986, Cellular immunology.
[8] S. Kaufmann,et al. Crossrecognition by CD8 T cell receptor alpha beta cytotoxic T lymphocytes of peptides in the self and the mycobacterial hsp60 which share intermediate sequence homology. , 1995, European journal of immunology.
[9] A. Osterhaus,et al. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene. , 1993, Vaccine.
[10] R. Evans,et al. The effect of saponin, sterols and linoleic acid on the weight increase of growing rats , 1960, British Journal of Nutrition.
[11] L. S. Kind,et al. Antigenic, Adjuvant and Permeability Enhancing Properties of Melittin in Mice , 1981, Allergy.
[12] A. Sjölander,et al. Iscoms in parasitological research. , 1996, Parasitology today.
[13] M. Trudel,et al. Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine. , 1992, Vaccine.
[14] S. Stacey,et al. Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs). , 1996, Vaccine.
[15] A. Osterhaus,et al. Antigenicity and immunogenicity of recombinant envelope glycoproteins of SIVmac32H with different in vivo passage histories. , 1995, Vaccine.
[16] G. Trinchieri,et al. Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin 12 and its effects on the antibody response. , 1997, Cytokine.
[17] A. Osterhaus,et al. The iscom structure as an immune-enhancing moiety: experience with viral systems. , 1992, Research in immunology.
[18] R. Graziano,et al. Cytotoxicity mediated by human Fc receptors for IgG. , 1989, Immunology today.
[19] A. Osterhaus,et al. A novel generation of viral vaccines based on the ISCOM matrix. , 1995, Pharmaceutical biotechnology.
[20] A. Osterhaus,et al. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.
[21] T. Wrin,et al. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons . , 1994, AIDS research and human retroviruses.
[22] A. Osterhaus,et al. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. , 1997, The Journal of infectious diseases.
[23] J. Berzofsky,et al. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. , 1994, Journal of immunology.
[24] L. Hilgers,et al. Classical and new approaches to adjuvant use in domestic food animals. , 1990, Advances in veterinary science and comparative medicine.
[25] R. Pipkorn,et al. Antigenic presentation of small molecules and peptides conjugated to a preformed iscom as carrier. , 1987, Journal of immunological methods.
[26] B. Morein,et al. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. , 1988, The Journal of general virology.
[27] R. Baggs,et al. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. , 1995, Vaccine.
[28] M. Villacrés-Eriksson,et al. In vitro activation of antigen‐presenting cells (APC) by defined composition of Quillaja saponaria Molina triterpenoids , 1996, Clinical and experimental immunology.
[29] A. Osterhaus,et al. Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition , 1992, The Journal of experimental medicine.
[30] M. Hansson,et al. Immunogenicity in rabbits and monkeys of influenza ISCOMs conjugated with repeated sequences of the Plasmodium falciparum antigen Pf155/RESA , 1993, Parasite immunology.
[31] K. Maloy,et al. Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS , 1995, European journal of immunology.
[32] G. Reid,et al. Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid. , 1992, Vaccine.
[33] J. Campbell,et al. Immune responses of mice to inactivated rabies vaccine administered orally: potentiation by Quillaja saponin. , 1986, Canadian journal of microbiology.
[34] J. Heeney,et al. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines. , 1994, Vaccine.
[35] R. F. Cook,et al. Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines. , 1994, Vaccine.
[36] K. Heeg,et al. Vaccination of class I major histocompatibility complex (MHC)‐restricted murine CD8+ cytotoxic T lymphocytes towards soluble antigens: immunostimulating‐ovalbumin complexes enter the class I MHC‐restricted antigen pathway and allow sensitization against the immunodominant peptide , 1991, European journal of immunology.
[37] C. Fossum,et al. Antigen‐Specific Increases in the Number of Splenocytes Expressing MHC Class II Molecules Following Restimulation with Antigen in Various Physical Forms , 1992, Scandinavian journal of immunology.
[38] M. Kazanji,et al. Immune responses and protective effect in mice vaccinated orally with surface sporozoite protein of Eimeria falciformis in ISCOMs. , 1994, Vaccine.
[39] K. Heeg,et al. Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells. , 1994, Vaccine.
[40] C. Fossum,et al. Interactions between Immune‐Stimulating Complexes (ISCOMs) and Peritoneal Mononuclear Leucocytes , 1992, Microbiology and immunology.
[41] D. O'hagan,et al. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. , 1994, Immunology.
[42] B. Askonas,et al. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro , 1989, The Journal of experimental medicine.
[43] E. Dotsika,et al. ISCOMs vaccine against experimental leishmaniasis. , 1998, Vaccine.
[44] A. Osterhaus,et al. Canine distemper virus (CDV) immune-stimulating complexes (Iscoms), but not measles virus iscoms, protect dogs against CDV infection. , 1988, The Journal of general virology.
[45] C. Fossum,et al. Effect of iscoms and their adjuvant moiety (matrix) on the initial proliferation and IL-2 responses: comparison of spleen cells from mice inoculated with iscoms and/or matrix. , 1990, Cellular immunology.
[46] A. Sjölander,et al. Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. , 1997, Cellular immunology.
[47] J. F. Young,et al. Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant. , 1992, Vaccine.
[48] C. Kensil,et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. , 1994, Vaccine.
[49] A. Sjölander,et al. Kinetics, localization and cytokine profile of T cell responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins. , 1997, Vaccine.
[50] B. Rönnberg,et al. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. , 1995, Vaccine.
[51] E. C. Beuvery,et al. On the structure of immune-stimulating saponin-lipid complexes (iscoms). , 1991, Biochimica et biophysica acta.
[52] K. Simons,et al. Subunit vaccines against enveloped viruses: virosomes, micelles and other protein complexes. , 1985, Vaccine.
[53] R. F. Cook,et al. Responses of ponies to equid herpesvirus-1 ISCOM vaccination and challenge with virus of the homologous strain. , 1993, Research in veterinary science.
[54] G. Nest,et al. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. , 1994, Journal of immunology.
[55] M. Hansson,et al. High antibody responses in rabbits immunized with influenza virus ISCOMs containing a repeated sequence of the Plasmodium falciparum antigen Pf155/RESA. , 1991, Vaccine.
[56] C. Hart,et al. Stimulation of rotavirus IgA, IgG and neutralising antibodies in baboon milk by parenteral vaccination , 1995, Vaccine.
[57] J. Hansen,et al. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[58] K. Lövgren,et al. Conjugation of synthetic peptides to carrier iscoms: factors affecting the immunogenicity of the conjugate. , 1994, Journal of immunological methods.
[59] B. Vanselow,et al. A bovine ephemeral fever vaccine incorporating adjuvant Quil A: a comparative study using adjuvants Quil A, aluminium hydroxide gel and dextran sulphate , 1985, Veterinary Record.
[60] T. Fujioka,et al. Structure of desacylsaponins obtained from the bark of Quillaja saponaria , 1986 .
[61] D. Davis,et al. Characterization of canine humoral immune responses to outer surface protein subunit vaccines and to natural infection by Lyme disease spirochetes. , 1995, The Journal of infectious diseases.
[62] B. McGwire,et al. Iscom of viral envelope proteins protects against Aujeszky's disease. , 1989, Veterinary microbiology.
[63] A. Sjölander,et al. Adjuvant activity of iscoms; effect of ratio and co-incorporation of antigen and adjuvant. , 1996, Vaccine.
[64] L. Arthur,et al. Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120). , 1989, Vaccine.
[65] M. Villacrés-Eriksson,et al. Involvement of Interleukin‐2 and Interferon‐Gamma in the Immune Response Induced by Influenza Virus Iscoms , 1992, Scandinavian journal of immunology.
[66] C. Kensil,et al. Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant. , 1994, AIDS research and human retroviruses.
[67] M. Pepys,et al. Activation of mouse complement by different classes of mouse antibody. , 1979, Immunology.
[68] D. Hockley,et al. Antibody responses and protection in mice immunized with herpes simplex virus type 1 antigen immune-stimulating complex preparations. , 1989, The Journal of general virology.
[69] A. Lundén,et al. Immune responses in sheep after immunization with Toxoplasma gondii antigens incorporated into iscoms. , 1995, Veterinary parasitology.
[70] M. Villacrés-Eriksson,et al. In vivo and in vitro induction of IL-6 by Quillaja saponaria molina triterpenoid formulations. , 1997, Cytokine.
[71] H. Grey,et al. Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line , 1977, The Journal of experimental medicine.
[72] I. Johnson,et al. Brown Norway rat model of food allergy: effect of plant components on the development of oral sensitization. , 1996, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[73] O. Jarrett,et al. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. , 1991, Immunology.
[74] J. Berzofsky,et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. , 1993, Science.
[75] A. Osterhaus,et al. Measles virus fusion protein presented in an immune-stimulating complex (iscom) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells and protection in mice. , 1988, The Journal of general virology.
[76] M. Villacrés-Eriksson. Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes , 1995, Clinical and experimental immunology.
[77] A. Osterhaus,et al. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5) , 1995, Journal of virology.
[78] K. Maloy,et al. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. , 1993, Immunology.
[79] A. Delmas,et al. Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMs and induction of CTL responses following intranasal immunization. , 1996, Vaccine.
[80] C. Kensil,et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. , 1992, Journal of immunology.
[81] A. Allison,et al. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. , 1986, Journal of immunological methods.
[82] M. Ozel,et al. Quaternary structure of the immunostimulating complex (iscom). , 1989, Journal of ultrastructure and molecular structure research.
[83] W. Morrow,et al. Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[84] M. Trudel,et al. Vaccination of rabbits with a bovine herpesvirus type 1 subunit vaccine: adjuvant effect of ISCOMs. , 1987, Vaccine.
[85] B. Morein,et al. Cellular Immune Responses in the Murine Lung to Local Immunization with Influenza A Virus Glycoproteins in Micelles and Immunostimulatory Complexes (Iscoms) , 1988, Scandinavian journal of immunology.
[86] B. Morein. Iscom--an immunostimulating complex. , 1987, Arzneimittel-Forschung.
[87] L. Huang,et al. Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes. , 1993, Vaccine.
[88] I. Barr,et al. ISCOMs (immunostimulating complexes): The first decade , 1996, Immunology and cell biology.
[89] I. Barr,et al. ISCOMs and other saponin based adjuvants. , 1998, Advanced drug delivery reviews.
[90] K. Nagaraja,et al. A type-specific avian influenza virus subunit vaccine for turkeys: induction of protective immunity to challenge infection. , 1994, Vaccine.
[91] B. Moss,et al. Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes. , 1994, The Journal of general virology.
[92] T. Baldwin,et al. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. , 1998, Journal of immunology.
[93] C. Kensil,et al. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. , 1991, Journal of immunology.
[94] Y. S. Kwon,et al. Effect of a novel saponin adjuvant derived from Quillaja saponaria on the immune response to recombinant hepatitis B surface antigen. , 1997, Molecules and cells.
[95] Induction of CD8+ cytotoxic T-cells by immunization with purified HIV-1 envelope protein in ISCOMs. , 1991, Disease markers.
[96] J. Berzofsky,et al. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs , 1990, Nature.
[97] K. Lövgren,et al. Immunopotentiation of synthetic oligopeptides by chemical conjugation to iscoms. , 1993, Journal of immunological methods.
[98] D. Emery,et al. Influence of antigens and adjuvants on the production of gamma‐interferon and antibody by ovine lymphocytes , 1990, Immunology and cell biology.
[99] A. Osterhaus,et al. Serological responses in cats vaccinated with FeLV ISCOM and an inactivated FeLV vaccine. , 1989, Vaccine.
[100] T. Baldwin,et al. Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. , 1998, Vaccine.
[101] M. Villacrés-Eriksson,et al. Influence of Quillaja saponaria Triterpenoid Content on the Immunomodulatory Capacity of Epstein–Barr Virus Iscoms , 1997, Scandinavian journal of immunology.
[102] S. Alenius,et al. Protective effect of an ISCOM bovine virus diarrhoea virus (BVDV) vaccine against an experimental BVDV infection in vaccinated and non-vaccinated pregnant ewes. , 1991, Vaccine.
[103] H. Rammensee,et al. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine , 1989, Nature.
[104] A. Osterhaus,et al. ISCOMs and immunostimulation with viral antigens. , 1989, Sub-cellular biochemistry.
[105] A. Mowat,et al. Preservation of mucosal and systemic adjuvant properties of ISCOMS in the absence of functional interleukin‐4 or interferon‐γ , 1998, Immunology.
[106] M. Browning,et al. Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralizing antibodies. , 1992, Vaccine.
[107] D. Taub,et al. Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. , 1995, Journal of the National Cancer Institute.
[108] C. Kensil,et al. Structural and immunological characterization of the vaccine adjuvant QS-21. , 1995, Pharmaceutical biotechnology.
[109] M. Tomasi. 13 – ISCOMs, Liposomes, and Oil-Based Vaccine Delivery Systems , 1996 .
[110] A. Osterhaus,et al. Antigen detection in vivo after immunization with different presentation forms of rabies virus antigen: involvement of marginal metallophilic macrophages in the uptake of immune‐stimulating complexes , 1995, European journal of immunology.
[111] A. Osterhaus,et al. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. , 1997, The Journal of general virology.
[112] D. Gerlier,et al. Humoral immune response elicited in rats by measles viral membrane antigens presented in liposomes and ISCOMs. , 1988, Vaccine.
[113] C. Kensil. Saponins as vaccine adjuvants. , 1996, Critical reviews in therapeutic drug carrier systems.
[114] R. Locksley,et al. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[115] W. Britt,et al. Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice. , 1995, The Journal of infectious diseases.
[116] B. Morein,et al. The requirement of lipids for the formation of immunostimulating complexes (iscoms) , 1988, Biotechnology and applied biochemistry.
[117] K. Nagaraja,et al. A lipid-conjugated immunostimulating complex subunit vaccine against Salmonella infection in turkeys. , 1993, Avian diseases.
[118] P. Heegaard,et al. Iscom immunization with synthetic peptides representing measles virus hemagglutinin. , 1992, Virus research.
[119] S. Kaufmann,et al. Crossrecognition by CD8 T cell receptor αβ cytotoxic T lymphocytes of peptides in the self and the mycobacterial hsp60 which share intermediate sequence homology , 1995, European journal of immunology.
[120] L. Stipkovits,et al. Protective immunity induced in chicken by a single immunization with Mycoplasma gallisepticum immunostimulating complexes (ISCOMS). , 1996, Vaccine.
[121] C. Kensil,et al. Efficacy and safety field trials of a recombinant DNA vaccine against feline leukemia virus infection. , 1991, Journal of the American Veterinary Medical Association.
[122] J. Löwer,et al. Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. , 1995, Vaccine.
[123] J. Cleland. Design and production of single-immunization vaccines using polylactide polyglycolide microsphere systems. , 1995, Pharmaceutical biotechnology.
[124] W. Gause,et al. Early IL-4 production does not predict susceptibility to Leishmania major. , 1996, Experimental parasitology.
[125] E. C. Beuvery,et al. Incorporation of the major outer membrane protein of Neisseria gonorrhoeae in saponin-lipid complexes (iscoms): chemical analysis, some structural features, and comparison of their immunogenicity with three other antigen delivery systems , 1988, Infection and immunity.
[126] F. Chiodi,et al. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. , 1994, Journal of acquired immune deficiency syndromes.
[127] A. J. George. LEGAL STATUS AND TOXICITY OF SAPONINS. , 1965, Food and cosmetics toxicology.
[128] A. Sjölander,et al. Kinetics, Localization and Isotype Profile of Antibody Responses to Immune Stimulating Complexes (Iscoms) Containing Human Influenza Virus Envelope Glycoproteins , 1996, Scandinavian journal of immunology.
[129] K. Heeg,et al. The immunodominant peptide from listeriolysin in Quil A liposomes vaccinates CD8+ cytolytic T cells and confers protection to infection. , 1994, Immunology letters.
[130] M. Trudel,et al. Experimental polyvalent ISCOMs subunit vaccine induces antibodies that neutralize human and bovine respiratory syncytial virus. , 1989, Vaccine.
[131] S. Höglund,et al. Influenza virus ISCOMs: biochemical characterization. , 1988, Vaccine.
[132] Defining protective responses to pathogens: cytokine profiles in leprosy lesions. , 1991, Science.
[133] A. Osterhaus,et al. Canine distemper virus ISCOMs induce protection in harbour seals (Phoca vitulina) against phocid distemper but still allow subsequent infection with phocid distemper virus-1. , 1992, Vaccine.